share_log

Barclays Maintains Equal-Weight on Editas Medicine, Lowers Price Target to $3

Benzinga ·  Dec 13 22:58  · Ratings

Barclays analyst Gena Wang maintains Editas Medicine (NASDAQ:EDIT) with a Equal-Weight and lowers the price target from $5 to $3.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment